EGFR and anti-EGFR nanobodies: review and update. (21st April 2021)

• Record Type: Journal Article
• Authors: Sharifi, Jafar; Khirehgesh, Mohammad Reza; Safari, Fatemeh; Akbari, Bahman
• Is Part Of: Journal of drug targeting. Volume 29:Number 4(2021)
• Page Start: 387
• Page End: 402
• Publication Date: 2021-04-21
• Subjects: Nanobody -- EGFR -- diagnose and therapy -- EGFR overexpressing tumours -- EGFR targeting; Drug delivery systems -- Periodicals; Drug Delivery Systems; Vehicles; Drug Administration Routes; Drug Evaluation; 615.7
• DOI: 10.1080/1061186X.2020.1853756
• Languages: English
• ISSNs: 1061-186X

Abstract

Abstract: Targeted therapy is one of the favourable methods used in cancer treatment. Several recombinant proteins and small-molecules used for this aim include monoclonal antibodies, antibody fragments and peptides. Nanobody (Nb) is a camelid antibody fragment that is very effective in targeted therapy. Recently, several anti-EGFR (epidermal growth factor receptor) Nbs have been developed and utilised for diagnosis and therapy of EGFR overexpressing tumours. Anti-EGFR Nbs are used in drug delivery systems, photodynamic therapy (PDT) and/or conjugated to other molecules such as quantum dots (QDs), nanoparticles, liposome, tumour penetration peptides, neural stem cells (NSCs) and chimeric antigen receptor T cells (CAR T cells). In this review, we discussed the structure and function of EGFR and Nb, the current status of EGFR targeting, and recent developments in anti-EGFR Nbs. To gain sound insight into the issue at hand, we focused on the most powerful anti-EGFR Nbs.